Trevi Therapeutics Q3 net loss narrows, cash runway extended into 2028

Trevi Therapeutics

13/11/2025 21:31

Overview

Trevi Therapeutics' Q3 net loss narrows to $11.8 mln from $13.2 mln in 2024

Company preparing to initiate Phase 3 program for chronic cough in IPF in 2026

Trevi ends Q3 with $194.9 mln in cash, runway expected into 2028

Outlook

Company plans to initiate Phase 3 program for chronic cough in IPF in H1 2026

Trevi expects cash runway to last into 2028

Company plans to start Phase 2b RCC study in first half of 2026

Result Drivers

OTHER INCOME - Increased to $2.1 mln from $0.8 mln due to interest income from higher invested cash equivalent and marketable securities balances

R&D EXPENSES - Fell by $1.1 mln due to decreased clinical development expenses for Phase 2a RIVER trial, Human Abuse Potential study, and Phase 2b CORAL trial

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 EPS
-$0.08
Q3 Net Income
-$11.80 mln
Q3 Income from Operations
-$13.92 mln
Q3 Operating Expenses
$13.92 mln
Q3 Pretax Profit
-$11.82 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Trevi Therapeutics Inc is $20.00, about 40.8% above its November 12 closing price of $11.85

Press Release: ID:nPn800Y9Na

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)